Pfizer Global Medical Grants Announces a New Research RFP in Obesity

Pfizer supports the global healthcare community’s independent initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Date RFP Issued: September 20, 2021

Geographic Scope: Global

Clinical Area: Obesity

Link to full RFP: 2021/2022 Global Obesity ASPIRE

Letter of Intent (LOI) Due Date: November 5, 2021

Specific Area of Interest: Research in the following areas will be considered:

•             Pathophysiology and biology of overweight and obesity

•             Understanding Obesity as a disease

•             Utilizing retrospective databases, generate evidence of optimal management of obesity and co-existing comorbid conditions

Types of research in scope for this RFP are:

•             Basic science, pre-clinical research, and clinical research that aligns with the in-scope research topics.

•             Animal experimentation related to human biology.

•             Physiological, cellular, molecular and translational research

               

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Jessica Romano, Grant Officer (jessica.romano@pfizer.com).

 

               

 

 

Clinical Category
Health Promotion
Target Audience
Commissioners of care and other obesity interested organisation representatives
Healthcare professionals
Movement and Exercise professionals
Researchers